Current standards and progress in understanding and treatment of GIST.

Détails

Ressource 1Télécharger: 19234877.pdf (404.46 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_3A83608E103C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Current standards and progress in understanding and treatment of GIST.
Périodique
Swiss medical weekly
Auteur⸱e⸱s
Dirnhofer S., Leyvraz S.
ISSN
1424-7860 (Print)
ISSN-L
0036-7672
Statut éditorial
Publié
Date de publication
21/02/2009
Peer-reviewed
Oui
Volume
139
Numéro
7-8
Pages
90-102
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Résumé
Gastrointestinal stromal tumours (GIST), despite being rare, pose a relevant medical problem from the viewpoint of diagnosis and management. GIST are fragile, liable to metastasize and often located in delicate structures. Surgical options, therefore, are limited. In the last decade an improved understanding of the molecular mechanisms of the disease has resulted in novel modes of treatment. The introduction of systemic tyrosine kinase inhibitor therapy with imatinib has significantly improved the outcome of the disease and prolonged the survival of GIST patients. For many patients the acute threat of a deadly cancer has been transformed into a manageable chronic condition. Drug safety, tolerability and compliance, subjects of concern in all long-term therapies, have proven to be acceptable for the tyrosine kinase inhibitor imatinib. The present paper provides a compact overview of the epidemiology, pathophysiology and morphology of GIST, with special reference to the underlying molecular biology. Relevant aspects of diagnosis, therapy and monitoring of the disease are reviewed with particular emphasis on the available clinical evidence and recent guidelines.

Mots-clé
Antineoplastic Agents/pharmacology, Antineoplastic Agents/therapeutic use, Benzamides, Gastrointestinal Stromal Tumors/diagnosis, Gastrointestinal Stromal Tumors/drug therapy, Gastrointestinal Stromal Tumors/surgery, Humans, Imatinib Mesylate, Piperazines/pharmacology, Piperazines/therapeutic use, Protein Kinase Inhibitors/pharmacology, Protein Kinase Inhibitors/therapeutic use, Pyrimidines/pharmacology, Pyrimidines/therapeutic use, Receptor Protein-Tyrosine Kinases/antagonists & inhibitors, Receptor Protein-Tyrosine Kinases/physiology
Pubmed
Web of science
Création de la notice
24/02/2009 13:08
Dernière modification de la notice
20/08/2019 13:30
Données d'usage